Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat 3 Stocks Under $5 With Strong Analyst Upside PotentialReported by Chris Markoch. Published: 2/24/2026. 
Summary - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
While many investors are rotating out of speculative penny stocks, others still embrace their risk-reward dynamic. Stocks that trade for under $5 carry added risk: many are unprofitable and some generate little to no revenue. Moreover, most of these are small-cap companies, a group that has been beaten up in recent years. Even though the Russell 2000 shows signs of growth, that improvement hasn't broadly lifted the small-cap sector. That could change in 2026, particularly if the economic outlook improves and money flows back into speculative names. As with any market segment, however, quality matters. One way to filter for quality is to look for stocks with positive analyst sentiment. These three names fit that bill — each lets investors establish a sizable position with a modest outlay and offers potential for significant upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market stocks could be among the winners in 2026. That hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year to date. Based in Singapore, Grab operates a super app that combines technology, e-commerce and fintech services. One reason behind the recent pullback is its proposed merger with Indonesian ride-hailer GoTo. The deal is not final and may face significant legislative changes in Indonesia that could limit Grab's earnings potential there. The company also slightly missed the top line in its Q4 2025 earnings report. For context, revenue rose 19% year over year (YOY), and the year marked Grab's first full year of profitability. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That helps explain the continued bullish sentiment. GRAB has a consensus price target of $6.47, about 54% above its current level. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector to balance risk and reward. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), which at the time of writing traded just above $0.60 per share. VXRT has limited analyst coverage; the only analyst to rate it in the past 12 months lists it as a Buy with a $2 price target. It's not uncommon for analysts to overlook early-stage biotech firms. Vaxart is a clinical-stage company, meaning all its candidates are still in clinical trials. The upside is straightforward: Vaxart is developing oral vaccines for influenza, norovirus and COVID-19. Beyond the convenience and avoidance of needle-related fear, the company says its platform may induce a wider immune response that could provide broader protection. Institutional ownership is modest at about 18%, but by dollar volume inflows outnumber outflows nearly 10:1, suggesting concentrated interest despite low coverage. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down roughly 33% so far in 2026, but it helps to take a longer view: the stock is up more than 66% over the past 12 months, making the recent decline look like a typical pullback as investors shy away from unprofitable companies. In ThredUp's case, the caveat "yet" matters. The company runs an online consignment and thrift platform that is gaining traction with Gen Z, as reflected in its revenue. In the most recent quarter, revenue rose 12.5% YOY. ThredUp cites a GlobalData 2025 market survey forecasting the U.S. secondhand market's gross merchandise value will grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutional investors own an impressive 89% of TDUP. Dollar-volume buying has outpaced selling roughly 2:1, and the number of buyers exceeds sellers about 3:1. That said, short interest sits near 17%, which can add short-term volatility. The consensus price target from six analysts is $12.50, which would represent more than 190% upside from its price at the time of writing.
| 
